On February 6, 2007, Heritage Pharma Avet secured ANDA077345 approval, a pivotal move that signals the expansion of the company's generic portfolio into the new therapeutic segment, a segment projected to drive substantial revenue growth amidst increasing demand. This regulatory victory enhances Heritage Pharma's market positioning by diversifying its portfolio ahead of anticipated industry consolidation and prescription trends.